Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12968/hmed.2022.0240 | DOI Listing |
BMJ Case Rep
January 2025
Department of Laboratories, Philippine General Hospital, Manila, Philippines.
Synovial sarcoma is a rare malignant mesenchymal tumour typically found in the extremities, but it can also develop in the gastrointestinal tract, with the upper rectum being the most common site. We describe a case of a man in his 60s diagnosed with monophasic synovial sarcoma in the lower rectum, presenting with severe, intractable anal pain.
View Article and Find Full Text PDFOrthop Traumatol Surg Res
January 2025
Ankara University Medical Faculty, İbni Sina Hospital, Department of Orthopedics and Traumatology, Talatpasa Boulevard no:82, 06630 Ankara, Turkey.
Background: Synovial sarcoma (SS) is classified as an aggressive high-grade soft tissue sarcoma that predominantly affects the extremities. Despite its prevalence in the extremities (up to 80%), diagnostic and treatment challenges persist. This study aims to address these challenges by providing a comprehensive analysis of SS in extremities, focusing on diagnostic accuracy and treatment outcomes.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Department of Pathology, An-Najah National University Hospital, Nablus, Palestine.
Introduction And Importance: Synovial sarcoma is a malignant soft tissue tumor primarily affects the extremities. Its presence in the paranasal sinuses, especially within the ethmoid sinus, is exceedingly rare.
Case Presentation: We report a case of monophasic synovial sarcoma of the ethmoid sinus in a 54-year-old woman, who presented with 3 months history of left eye pain and bulging.
Cancer Immunol Immunother
December 2024
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Int J Surg Case Rep
January 2025
Pathology Department, National Medical Center "20 de Noviembre", Mexico City, MX. Mexico.
Introduction And Importance: Synovial sarcoma (SS) is a high-grade malignancy, accounting for 2.5-3.5 % of all primary H&N sarcomas and 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!